Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML

S. S. Ettou (1, 2, 3) , E. E. Audureau (3, 4) , C. C. Humbrecht (1, 2, 3) , B. B. Benet (1, 2, 3) , Hélène Jammes (5) , T. T. Clozel (3) , V. V. Bardet (1, 2, 3, 4) , C. C. Lacombe (1, 2, 3, 4) , F. F. Dreyfus (1, 2, 3, 4) , P. P. Mayeux (1, 2, 3) , E. E. Solary (3, 6) , M. M. Fontenay (1, 2, 3, 4)

1 [Institut Cochin] Departement Infection, immunité, inflammation
2 IC UM3 (UMR 8104 / U1016) - Institut Cochin
3 UPD5 Médecine - Université Paris Descartes - Faculté de Médecine
4 Hôpital Cochin [AP-HP]
5 BDR - Biologie du développement et reproduction
6 Hématopoïèse normale et pathologique

absent

Mots clés: myelodysplastic syndrome; secondary acute myeloid leukemia

Domaines: Sciences agricoles

S. S. Ettou, E. E. Audureau, C. C. Humbrecht, B. B. Benet, Hélène Jammes, et al.. Fas expression at diagnosis as a biomarker of azacitidine activity in high-risk MDS and secondary AML. Leukemia, 2012, 26 (10), pp.2297-2299. ⟨10.1038/leu.2012.152⟩. ⟨hal-01004302⟩